A New CYP2E1 Inhibitor, 12‐Imidazolyl‐1‐dodecanol, Represents a Potential Treatment for Hepatocellular Carcinoma
Canadian Journal of Gastroenterology and Hepatology · 2021-01 · 2021 (1)
DOI: 10.1155/2021/8854432 ↗Kurz gefasst
Fachartikel in der Zeitschrift Canadian Journal of Gastroenterology and Hepatology, online erschienen am 02.02.2021. Verfasst von Torsten Diesinger und 20 weiteren Autor:innen. Beteiligte Einrichtung: Chair of Biochemistry and Molecular Medicine, Witten/Herdecke University, Faculty of Health/School of Medicine, Alfred-Herrhausen-Straße 50, 58448 Wi…. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Cytochrome P450 2E1 (CYP2E1) is a key target protein in the development of alcoholic and nonalcoholic fatty liver disease (FLD). The pathophysiological correlate is the massive production of reactive oxygen species. The role of CYP2E1 in the development of hepatocellular carcinoma (HCC), the final complication of FLD, remains controversial. Specifically, CYP2E1 has not yet been defined as a molecular target for HCC therapy. In addition, a CYP2E1‐specific drug has not been developed. We have already shown that our newly developed CYP2E1 inhibitor 12‐imidazolyl‐1‐dodecanol (I‐ol) was therapeutically effective against alcoholic and nonalcoholic steatohepatitis. In this study, we investigated the effect of I‐ol on HCC tumorigenesis and whether I‐ol could serve as a possible treatment option for terminal‐stage FLD. I‐ol exerted a very highly significant antitumour effect against hepatocellular HepG2 cells. Cell viability was reduced in a dose‐dependent manner, with only the highest doses causing a cytotoxic effect associated with caspase 3/7 activation. Comparable results were obtained for the model colorectal adenocarcinoma cell line, DLD‐1, whose tumorigenesis is also associated with CYP2E1. Transcriptome analyses showed a clear effect of I‐ol on apoptosis and cell‐cycle regulation, with the increased expression of p27Kip1 being particularly noticeable. These observations were confirmed at the protein level for HepG2 and DLD‐1 cells grafted on a chorioallantoic membrane. Cell‐cycle analysis showed a complete loss of proliferating cells with a simultaneous increase in S‐phase arrest beginning at a threshold dose of 30 μ M. I‐ol also reduced xenograft tumour growth in nude mice. This antitumour effect was not associated with tumour cachexia. I‐ol was not toxic to healthy tissues or organs. This study demonstrates for the first time the therapeutic effect of the specific CYP2E1 inhibitor I‐ol on the tumorigenesis of HCC. Our findings imply that I‐ol can potentially be applied therapeutically on patients at the final stage of FLD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Chair of Biochemistry and Molecular Medicine, Witten/Herdecke University, Faculty of Health/School of Medicine, Alfred-Herrhausen-Straße 50, 58448 Witten, Germany.
- Institute of Physiological Chemistry, University of Ulm, Albert-Einstein-Allee 11, 89081 Ulm, Germany.
- Department of Internal Medicine, Neu-Ulm Hospital, Krankenhausstraße 11, 89231 Neu-Ulm, Germany.
- Department of Internal Medicine II, University Hospital Ulm, Albert-Einstein-Allee 23, 89081 Ulm, Germany.
- Institute of Biochemistry and Molecular Biology II, Medical Faculty of the Heinrich Heine University Düsseldorf, Moorenstraße 5, 40225 Düsseldorf, Germany.
- Max Planck Institute of Molecular Physiology, Otto-Hahn-Straße 11, 44227 Dortmund, Germany.
ORCID-Profile: Torsten Diesinger
Zitieren
APA
Diesinger, T., Lautwein, A., Bergler, S., Buckert, D., Renz, C., Dvorsky, R., Buko, V., Kirko, S., Schneider, E., Kuchenbauer, F., Kumar, M., Günes, C., Genze, F., Büchele, B., Simmet, T., Haslbeck, M., Masur, K., Barth, T., Müller-Enoch, D., …, & Haehner, T. (2021). A New CYP2E1 Inhibitor, 12‐Imidazolyl‐1‐dodecanol, Represents a Potential Treatment for Hepatocellular Carcinoma. Canadian Journal of Gastroenterology and Hepatology, 2021(1). https://doi.org/10.1155/2021/8854432
Vancouver
Diesinger T, Lautwein A, Bergler S, Buckert D, Renz C, Dvorsky R, et al. A New CYP2E1 Inhibitor, 12‐Imidazolyl‐1‐dodecanol, Represents a Potential Treatment for Hepatocellular Carcinoma. Canadian Journal of Gastroenterology and Hepatology. 2021;2021(1). doi:10.1155/2021/8854432
BibTeX
@article{Diesinger2021,
author = {Diesinger, Torsten and Lautwein, Alfred and Bergler, Sebastian and Buckert, Dominik and Renz, Christian and Dvorsky, Radovan and Buko, Vyacheslav and Kirko, Siarhei and Schneider, Edith and Kuchenbauer, Florian and Kumar, Mukesh and Günes, Cagatay and Genze, Felicitas and Büchele, Berthold and Simmet, Thomas and Haslbeck, Martin and Masur, Kai and Barth, Thomas and Müller-Enoch, Dieter and Wirth, Thomas and Haehner, Thomas},
title = {A New CYP2E1 Inhibitor, 12‐Imidazolyl‐1‐dodecanol, Represents a Potential Treatment for Hepatocellular Carcinoma},
journal = {Canadian Journal of Gastroenterology and Hepatology},
year = {2021},
volume = {2021},
number = {1},
doi = {10.1155/2021/8854432}
}
EUVIMED